Brief: Galecto Says Top-Line Results From GULLIVER-2 Trial On Track For Q4

Damora Therapeutics

29/03/2022 14:20

March 29 (Reuters) - Galecto Inc  GLTO.O :
    * GALECTO COMPLETES ENROLLMENT IN PHASE 1B/2A GULLIVER-2
TRIAL OF
ITS SELECTIVE, ORAL GALECTIN-3 INHIBITOR GB1211 IN LIVER
CIRRHOSIS
    * GALECTO INC - TOP-LINE RESULTS FROM GULLIVER-2 TRIAL ON
TRACK
FOR Q4 OF 2022

Source text for Eikon:  ID:nGNXF5tJH 
Further company coverage:  GLTO.O 

 ((Reuters.Briefs@thomsonreuters.com;))